MariMed Inc. is a U.S.-based multi-state cannabis operator that develops, owns, and manages licensed cultivation, production, and dispensary operations for medicinal and adult-use cannabis. The company also builds consumer brands and licenses those brands in select domestic markets, combining retail, wholesale, and managed-services revenue streams.
3,3 %
36,2 %
−9,1 %
+1,3 %
1.00
0.38
| % | |
|---|---|
| Retail cannabis sales | 45% Direct sales of cannabis and cannabis-infused products through company dispensaries. |
| Wholesale branded products | 35% Sales of MariMed-owned brands to third-party dispensaries and wholesalers. |
| Managed services and licensing | 10% Management fees, licensing fees, and operational support for cannabis license holders. |
| Real estate and procurement services | 10% Rental income and supply procurement fees tied to cannabis facilities and clients. |
MariMed sells primarily to cannabis consumers through its retail dispensaries and to wholesale buyers such as regulated...
Patients and adult-use customers buying cannabis flower, edibles, concentrates, and other products at MariMed stores.
Licensed retailers and wholesalers purchasing MariMed brands such as Betty's Eddies for resale.
Licensed operators that pay for day-to-day management, compliance, and operational oversight.
Cannabis-licensed clients leasing property or using MariMed-managed facilities and services.
MariMed operates in multiple U.S. states and is headquartered in Norwood, Massachusetts...
MariMed is focused on growing branded product revenue by improving cultivation, processing, innovation, and...
Branded products can scale across retail and wholesale channels and improve market share.
Company-owned stores provide direct consumer access, higher transaction frequency, and brand feedback.
These arrangements let MariMed monetize its operating expertise without relying only on owned stores.
MariMed operates in an industry where cannabis remains illegal under U.S. federal law, so state-by-state licensing and...
The company operates under state law while cannabis remains a Schedule I substance federally, creating legal and regulatory uncertainty.
Each market requires state and local approvals, and noncompliance could suspend or limit operations.
Competitors may offer more effective, easier-to-buy, or cheaper products, reducing MariMed sales and margins.
Growth has relied on acquisitions, which can bring contingent liabilities, debt, and goodwill impairment risk.
Operational systems and confidential data could be disrupted or compromised by cyber incidents.
Failure to meet continued listing standards could reduce liquidity and market value of the stock.
INM · Pharmaceutical Preparations
INSM · Pharmaceutical Preparations
INSMED Inc is a U.S.-based biopharmaceutical company focused on developing and commercializing therapies for serious respiratory and other high-unmet-need diseases.
VCEL · Biological Products, (No Diagnostic Substances)
Vericel Corp is a U.S.-based biopharmaceutical company focused on advanced therapies for cartilage repair and severe burn care.
MODD · Surgical & Medical Instruments & Apparatus
NSPR · Surgical & Medical Instruments & Apparatus
IRMD · Surgical & Medical Instruments & Apparatus
IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service.
: 28.4.2026